VA must disclose medication risks to veterans before prescribing psychiatric drugs

What it does

This bill requires the Veterans Affairs Department to expand its existing informed-consent directive for opioid therapy to cover five additional medication classes: antipsychotics, stimulants, antidepressants, anxiolytics, and narcotics. Veterans would receive written disclosure of risks and benefits before starting these medications, matching the transparency standard already applied to long-term opioid pain therapy.

Why we flagged it

The bill's sole operative mechanism is a directive to expand informed-consent requirements to additional medication classes. It is a straightforward patient-protection measure with no hidden provisions or narrow beneficiaries.

What the text implies

• Expansion may increase documentation burden on VA clinicians, potentially slowing prescribing workflows unless VA provides training and template updates.
• Veterans with cognitive impairment or severe psychiatric conditions may face barriers to consent; bill does not address capacity assessment or surrogate-decision protocols.
• Stimulant inclusion (ADHD medications) alongside narcotics and antipsychotics groups disparate drug classes under one consent standard, potentially conflating risk profiles.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Veterans gain explicit written disclosure and documented consent rights before receiving powerful psychiatric and pain medications, reducing risk of uninformed prescribing and strengthening their ability to make autonomous medical decisions. The bill imposes no new costs on veterans and aligns VA practice with informed-consent standards already established for opioids.

Named in the bill

Department of Veterans Affairs, Veterans Health Administration, VHA Directive 1005

Where it stands

29 cosponsors: 25 Republicans, 4 Democrats.

• Aug 1, 2025 — Introduced · Congress.gov: “Introduced in House”
• Aug 1, 2025 — Referred to House Committee on Veterans' Affairs · Congress.gov: “Referred to the House Committee on Veterans' Affairs”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

5 lobbying clients named this bill on 8 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $6,905,557 in lobbying spend. A filing names 103 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 78% of bills with at least one filing.

Gus Bilirakis, the sponsor, reported $885,250 in PAC receipts in the 2026 cycle.

• American Medical Association — $5,643,000 on 2 filings
• American Psychiatric Association — $529,365 on 2 filings
• American Psychological Association Services Inc.(fka American Psychological Assn — $340,000 on 1 filing
• Disabled American Veterans — $310,451 on 2 filings
• National Council for Behavioral Health — $82,741 on 1 filing

Lobbying Disclosure Act filings through Jul 21, 2026. A filing shows who paid to lobby on a bill it names, not what changed.